Olodaterol (BI 1744) placebo

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

CompletedNCT01040130

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-07-08

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

CompletedNCT01040793

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-07-08

Related Papers

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.

2016-07-0614 citations